JP2009536220A5 - - Google Patents

Download PDF

Info

Publication number
JP2009536220A5
JP2009536220A5 JP2009510112A JP2009510112A JP2009536220A5 JP 2009536220 A5 JP2009536220 A5 JP 2009536220A5 JP 2009510112 A JP2009510112 A JP 2009510112A JP 2009510112 A JP2009510112 A JP 2009510112A JP 2009536220 A5 JP2009536220 A5 JP 2009536220A5
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
halo
substituted
hedgehog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009510112A
Other languages
English (en)
Japanese (ja)
Other versions
JP4891396B2 (ja
JP2009536220A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/068292 external-priority patent/WO2007131201A2/en
Publication of JP2009536220A publication Critical patent/JP2009536220A/ja
Publication of JP2009536220A5 publication Critical patent/JP2009536220A5/ja
Application granted granted Critical
Publication of JP4891396B2 publication Critical patent/JP4891396B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009510112A 2006-05-05 2007-05-04 ヘッジホッグ経路調節剤としての化合物および組成物 Active JP4891396B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79794906P 2006-05-05 2006-05-05
US60/797,949 2006-05-05
PCT/US2007/068292 WO2007131201A2 (en) 2006-05-05 2007-05-04 Compounds and compositions as hedgehog pathway modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011189963A Division JP5603308B2 (ja) 2006-05-05 2011-08-31 ヘッジホッグ経路調節剤としての化合物および組成物

Publications (3)

Publication Number Publication Date
JP2009536220A JP2009536220A (ja) 2009-10-08
JP2009536220A5 true JP2009536220A5 (cg-RX-API-DMAC7.html) 2011-10-20
JP4891396B2 JP4891396B2 (ja) 2012-03-07

Family

ID=38668605

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009510112A Active JP4891396B2 (ja) 2006-05-05 2007-05-04 ヘッジホッグ経路調節剤としての化合物および組成物
JP2011189963A Active JP5603308B2 (ja) 2006-05-05 2011-08-31 ヘッジホッグ経路調節剤としての化合物および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011189963A Active JP5603308B2 (ja) 2006-05-05 2011-08-31 ヘッジホッグ経路調節剤としての化合物および組成物

Country Status (45)

Country Link
US (2) US8178563B2 (cg-RX-API-DMAC7.html)
EP (2) EP2363393B1 (cg-RX-API-DMAC7.html)
JP (2) JP4891396B2 (cg-RX-API-DMAC7.html)
KR (1) KR101076943B1 (cg-RX-API-DMAC7.html)
CN (2) CN101437800A (cg-RX-API-DMAC7.html)
AR (2) AR060858A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007247860C1 (cg-RX-API-DMAC7.html)
BE (1) BE2015C059I2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0711333B8 (cg-RX-API-DMAC7.html)
CA (1) CA2650248C (cg-RX-API-DMAC7.html)
CL (1) CL2007001269A1 (cg-RX-API-DMAC7.html)
CR (1) CR10399A (cg-RX-API-DMAC7.html)
CU (1) CU23760B7 (cg-RX-API-DMAC7.html)
CY (1) CY2015054I1 (cg-RX-API-DMAC7.html)
DK (1) DK2021328T3 (cg-RX-API-DMAC7.html)
EA (1) EA018302B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP088860A (cg-RX-API-DMAC7.html)
ES (2) ES2422557T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20105103B (cg-RX-API-DMAC7.html)
GT (1) GT200800237A (cg-RX-API-DMAC7.html)
HN (1) HN2008001652A (cg-RX-API-DMAC7.html)
HU (1) HUS1500065I1 (cg-RX-API-DMAC7.html)
IL (1) IL194818A (cg-RX-API-DMAC7.html)
JO (1) JO2883B1 (cg-RX-API-DMAC7.html)
LT (1) LTC2021328I2 (cg-RX-API-DMAC7.html)
LU (1) LU92883I2 (cg-RX-API-DMAC7.html)
MA (1) MA30426B1 (cg-RX-API-DMAC7.html)
ME (1) ME00417B (cg-RX-API-DMAC7.html)
MX (1) MX2008014190A (cg-RX-API-DMAC7.html)
MY (1) MY153574A (cg-RX-API-DMAC7.html)
NL (1) NL300790I1 (cg-RX-API-DMAC7.html)
NO (3) NO341215B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ572362A (cg-RX-API-DMAC7.html)
PE (1) PE20080418A1 (cg-RX-API-DMAC7.html)
PL (2) PL2363393T3 (cg-RX-API-DMAC7.html)
PT (2) PT2363393E (cg-RX-API-DMAC7.html)
SG (1) SG172680A1 (cg-RX-API-DMAC7.html)
SI (1) SI2021328T1 (cg-RX-API-DMAC7.html)
SM (1) SMP200800056B (cg-RX-API-DMAC7.html)
SV (1) SV2008003089A (cg-RX-API-DMAC7.html)
TN (1) TNSN08437A1 (cg-RX-API-DMAC7.html)
TW (1) TWI369352B (cg-RX-API-DMAC7.html)
UA (1) UA93548C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007131201A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200808962B (cg-RX-API-DMAC7.html)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA93548C2 (uk) * 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明(cyclopamine)類似物類
AU2014280951B2 (en) * 2007-06-07 2016-10-13 Sun Pharmaceutical Industries Limited Biphenylcarboxamide derivatives as hedgehog pathway modulators
ES2569941T3 (es) * 2007-06-07 2016-05-13 Novartis Ag Derivados de bifenilcarboxamida como moduladores de la ruta de hedgehog
EP2222638A2 (en) * 2007-11-21 2010-09-01 Decode Genetics EHF Biaryl pde4 inhibitors for treating inflammation
WO2009086451A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US20090281089A1 (en) * 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
KR101129088B1 (ko) * 2008-09-17 2012-03-23 노파르티스 아게 N-[6-(시스-2,6-디메틸모르폴린-4-일)피리딘-3-일]-2-메틸-4'-(트리플루오로메톡시)[1,1'-비페닐]-3-카르복스아미드의 염
CA2738868C (en) * 2008-10-01 2017-01-17 Novartis Ag Smoothened antagonism for the treatment of hedgehog pathway-related disorders
WO2010052448A2 (en) * 2008-11-05 2010-05-14 Ucb Pharma S.A. Fused pyrazine derivatives as kinase inhibitors
AR077490A1 (es) * 2009-07-21 2011-08-31 Novartis Ag Composiciones farmaceuticas topicas para el tratamiento de una condicion hiperproliferativa de la piel
CA2769795C (en) 2009-08-05 2020-01-07 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
US20110039850A1 (en) * 2009-08-12 2011-02-17 Mhairi Copland Leukemia Treatment
JP2013511526A (ja) * 2009-11-18 2013-04-04 ノバルティス アーゲー 固形腫瘍及びその他の悪性腫瘍を治療するための方法及び組成物
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ, インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
CN101993415B (zh) * 2010-09-15 2013-08-14 北京韩美药品有限公司 作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3238722B1 (en) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones
EP2715366B1 (en) 2011-06-02 2017-07-19 Novartis AG Biomarkers for hedgehog inhibitor therapy
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2878082A1 (en) 2012-09-17 2014-03-20 Duke University Smoothened modulators and methods of use thereof
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
EP2925363A4 (en) 2012-11-29 2016-11-09 Strasspharma Llc METHOD FOR MODULATING FOLLICLE-STIMULATING HORMONACTIVITY
CN103910736B (zh) * 2013-01-08 2017-11-17 江苏先声药业有限公司 一类二氢吡喃并嘧啶衍生物及其医药应用
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
KR20160013204A (ko) 2013-05-30 2016-02-03 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015092720A1 (en) * 2013-12-19 2015-06-25 Novartis Ag Metabolites of sonidegib (lde225)
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
JP6377245B2 (ja) * 2014-03-24 2018-08-22 グアンドン ジョンシェン ファーマシューティカル カンパニー リミテッド Smo阻害剤としてのキノリン誘導体
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
TWI706958B (zh) 2015-03-10 2020-10-11 美商艾杜諾生物科技公司 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法
WO2016155630A1 (zh) * 2015-03-30 2016-10-06 苏州晶云药物科技有限公司 N-[6-(顺式-2,6-二甲基吗啉-4-基)吡啶-3-基]-2-甲基-4'-(三氟甲氧基)[1,1'-联苯]-3-甲酰胺单磷酸盐的晶型及其制备方法
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
AU2016271432A1 (en) * 2015-06-05 2017-12-07 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
PT3370768T (pt) 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
US10239849B2 (en) 2015-11-12 2019-03-26 Merck Sharp & Dohme Corp. Cyanopyridine derivatives as liver X receptor beta agonists, compositions, and their use
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
US20170231968A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
WO2017163258A1 (en) * 2016-03-22 2017-09-28 Msn Laboratories Private Limited Process for the preparation of n-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2- methyl-4'-(trifiuoromethoxy) [1,1' -biphenyi]-3-carboxamide and its polymorphs thereof
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
EP4173639A4 (en) 2020-06-26 2024-03-13 RaQualia Pharma Inc. METHOD FOR SELECTING A CANCER PATIENT FOR WHICH COMBINATION THERAPY OF A RETINOID AND A CANCER TREATMENT AGENT WILL BE EFFECTIVE, AND COMBINATION DRUG OF A RETINOID AND A CANCER TREATMENT AGENT
EP4185279A4 (en) 2020-07-24 2024-05-01 Secura Bio, Inc. TREATING CANCER WITH PI3-KINASE ISOFORM MODULATORS
WO2023211256A1 (ko) * 2022-04-29 2023-11-02 제일약품주식회사 신규한 pim 키나아제 억제 화합물 및 이의 용도
CN117466866B (zh) * 2022-07-29 2026-03-24 首都医科大学附属北京天坛医院 Hedgehog信号通路抑制剂

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
JP2001519345A (ja) 1997-10-02 2001-10-23 メルク エンド カムパニー インコーポレーテッド プレニルタンパク質トランスフェラーゼの阻害剤
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US6335459B1 (en) 1998-12-23 2002-01-01 Syntex (U.S.A.) Llc Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators
WO2001044172A1 (en) 1999-12-15 2001-06-21 Axys Pharmaceuticals, Inc. Salicylamides as serine protease and factor xa inhibitors
WO2001044260A2 (en) 1999-12-17 2001-06-21 Ariad Pharmaceuticals, Inc. Novel purines
US20030187261A1 (en) 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
CA2413702A1 (en) * 2000-06-28 2002-01-03 Teva Pharmaceuticals Industries Ltd. Carvedilol
GB0022438D0 (en) 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
JP2002338537A (ja) 2001-05-16 2002-11-27 Mitsubishi Pharma Corp アミド化合物およびその医薬用途
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
JP2005538975A (ja) 2002-07-03 2005-12-22 アステックス テクノロジー リミテッド p38MAPキナーゼ阻害薬としての3−(ヘテロ)アリールメトキシピリジン類およびそれらの類縁体
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
WO2005020892A2 (en) * 2003-08-08 2005-03-10 Mitochroma Research, Inc. Pharmaceutical compositions and methods for metabolic modulation
US7544699B2 (en) 2003-08-08 2009-06-09 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7504401B2 (en) * 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
WO2005030206A1 (en) * 2003-09-24 2005-04-07 Imclone Systems Incorporated Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
AR046698A1 (es) 2003-11-11 2005-12-21 Ishihara Sangyo Kaisha Derivado bifenilo o su sal, y pesticida que lo contienen como un ingrediente activo
MXPA06007095A (es) 2003-12-22 2006-09-04 Gilead Sciences Inc Conjugados de fosfonato inhibidores de cinasa.
JP4903133B2 (ja) * 2004-04-30 2012-03-28 ジェネンテック,インコーポレイティド ヘッジホッグシグナル伝達のキノキサリン阻害剤
US7683097B2 (en) * 2004-05-27 2010-03-23 Propharmacon Inc. Topoisomerase inhibitors
WO2006028958A2 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
GB0420719D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
FR2876583B1 (fr) 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
ATE502025T1 (de) * 2004-10-19 2011-04-15 Compass Pharmaceuticals Llc Arylcarboxamide und ihre verwendung als antitumormittel
GT200500321A (es) 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
EP1844003A4 (en) 2005-01-27 2010-09-22 Astrazeneca Ab NEW BIAROMATIC COMPOUNDS AS INHIBITORS OF THE P2X7 RECEPTOR
WO2006118914A2 (en) * 2005-04-29 2006-11-09 Children's Medical Center Corporation Methods of increasing proliferation of adult mammalian cardiomyocytes through p38 map kinase inhibition
DK1885710T3 (en) 2005-05-18 2015-11-23 Janssen Pharmaceutica Nv SUBSTITUTED AMINOPROPENYLPIPERIDINE OR MORPHOLINE DERIVATIVES AS UNKNOWN INHIBITORS OF HISTONDEACETYLASE
ES2400371T3 (es) 2005-07-07 2013-04-09 Abbott Laboratories Promotores de la apoptosis
PL1940786T3 (pl) 2005-09-16 2010-12-31 Arrow Therapeutics Ltd Pochodne bifenylowe i ich zastosowanie w leczeniu zapalenia wątroby typu C
UA93548C2 (uk) * 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
US20080280891A1 (en) * 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
PE20080948A1 (es) 2006-07-25 2008-09-10 Irm Llc Derivados de imidazol como moduladores de la senda de hedgehog
PT2076268E (pt) 2006-10-19 2013-03-07 Genzyme Corp Roscovitina para o tratamento de certas doenças císticas
DE102006062203A1 (de) 2006-12-22 2008-06-26 Curacyte Discovery Gmbh Substituierte 5H-Pyrimido[5,4-b]indole als Induktoren der Apoptose bei B-CLL Zellen
ES2569941T3 (es) 2007-06-07 2016-05-13 Novartis Ag Derivados de bifenilcarboxamida como moduladores de la ruta de hedgehog
WO2009009041A2 (en) 2007-07-06 2009-01-15 Kinex Pharmaceuticals, Llc Compositions and methods for modulating a kinase cascade
JP2011506445A (ja) 2007-12-13 2011-03-03 アムジエン・インコーポレーテツド γ−セクレターゼ調節剤
WO2009078992A1 (en) 2007-12-17 2009-06-25 Amgen Inc. Linear tricyclic compounds as p38 kinase inhibitors

Similar Documents

Publication Publication Date Title
JP5289060B2 (ja) Parpインヒビターとの組合せ療法
US20130224151A1 (en) Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
JP2022520061A5 (cg-RX-API-DMAC7.html)
JP5232678B2 (ja) 新形成細胞の細胞消滅死を誘導する方法
EP2021328B1 (en) Compounds and compositions as hedgehog pathway modulators
JP2009541223A5 (cg-RX-API-DMAC7.html)
EP1416928A2 (en) N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents
RS52274B2 (sr) Jedinjenje diarilhidantoina
US20240299395A1 (en) Combination therapies comprising wee1 inhibitors and dna damage response (ddr) inhibitors
US20160324829A1 (en) Combination therapy with parp inhibitors
CN112166111A (zh) 治疗纤维化疾病的方法
TW202320758A (zh) 組合
WO2022133446A1 (en) Combinations
JP2013511526A (ja) 固形腫瘍及びその他の悪性腫瘍を治療するための方法及び組成物
US20090029966A1 (en) Combination therapy with parp inhibitors
US20120190720A1 (en) Combination Therapy With Parp Inhibitors
JP2024546584A (ja) Bcl-2阻害剤、wee-1阻害剤及び他の化学療法剤の三剤療法の組み合わせ
JP6962990B2 (ja) サルコイドーシスを処置するための1,3−プロパンジスルホン酸またはその薬学的に許容される塩の使用
JP2025532582A (ja) 組み合わせ
JP2003528144A5 (cg-RX-API-DMAC7.html)
US10507228B2 (en) Methods and compositions related to KRAS inhibitors
WO2016020408A2 (en) Compounds for preventing ototoxicity
US20080280867A1 (en) Combination therapy with parp inhibitors
ES2299692T3 (es) Terapia combinada contra tumores que comprende derivados de distmicina acriloil sustituido y radioterapia.
EP1623741A2 (en) Cannabinoid receptor ligands for hair growth modulation